Prevalencia de quejas subjetivas de memoria: estudio poblacional en España / Prevalence of subjective memory complaints: Population study in Spain

Introducción Las quejas subjetivas de memoria (QSM) pueden ser una señal inicial de un posterior deterioro de las funciones cognitivas. Sin embargo, no se han publicado estudios poblacionales cubriendo toda España para conocer la prevalencia de las QSM. El objetivo del presente estudio fue conocer la prevalencia de las QSM en la población general residente en España >50 años y, también qué actuaciones se llevaban a cabo al respecto. Materiales y métodos Se realizaron entrevistas mediante un cuestionario online/Computer Assisted Web Interview (CAWI) a una muestra representativa a nivel nacional >50 años. La encuesta constaba de 34 ítems divididos en 2 bloques. Se consideró presencia de QSM cuando en la pregunta 1 el sujeto contestaba que ‘Sí’ tenía algún problema de memoria. Resultados Se entrevistó a 2.300 personas (53,7% mujeres; 23,9% ≥75 años). El 31% contestaron que consideraban que tenían un problema de memoria (sin diferencias entre sexos, media de tiempo con problemas de memoria de 3,0 años). Se observó mayor prevalencia de QSM en ≥75 años (44%). El 90% no incluían ningún alimento específico en su dieta para sus problemas de memoria, y tampoco estaban tomando productos farmacéuticos, complementos de la dieta o suplementos nutricionales (92%). El 78% de los entrevistados con QSM no han consultado a profesionales sanitarios por sus problemas de memoria. Conclusiones Las QSM tienen una prevalencia considerable en nuestro medio, afectando a casi un tercio de los individuos >50 años. La mayoría de los entrevistados con quejas de memoria no buscó el consejo/recomendación de profesionales sanitarios con respecto a las mismas. (AU)

Introduction Subjective memory complaints (SMC) might be an early sign of further deterioration in cognitive functions. However, no population studies have been published covering all Spain to determine the SMC prevalence. The objective of the present study was to determine the SMC prevalence in the general population residing in Spain >50 years of age and also which related actions were done. Materials and methods Interviews were conducted with a nationally representative sample >50 years of age using an online/computer assisted web interview (CAWI) questionnaire. The survey consisted of 34 items divided into two blocks. Presence of SMC was considered when in question 1 the subject answered that “Yes” he had some memory problem. Results Two thousand three hundred people (53.7% women; 23.9% ≥75 years old) were interviewed. 31% answered that they considered they had a memory problem (no differences between sexes, mean time with memory problems of 3.0 years). A higher prevalence of SMC was observed in ≥75 years old (44%). 90% did not include any specific foods in their diet for their memory problems, neither were taking any pharmaceuticals, diet supplements or nutritional supplements (92%). 78% of those interviewed with SMC have not consulted health professionals for their memory problems. Conclusions SMC are considerably prevalent in our environment affecting almost a third of people ≥50 years of age. Most of the interviewees with SMC did not go to health professionals to manage their SMC. (AU)

Prevalencia de quejas subjetivas de memoria: estudio poblacional en España / Prevalence of subjective memory complaints: Population study in Spain

Introducción Las quejas subjetivas de memoria (QSM) pueden ser una señal inicial de un posterior deterioro de las funciones cognitivas. Sin embargo, no se han publicado estudios poblacionales cubriendo toda España para conocer la prevalencia de las QSM. El objetivo del presente estudio fue conocer la prevalencia de las QSM en la población general residente en España >50 años y, también qué actuaciones se llevaban a cabo al respecto. Materiales y métodos Se realizaron entrevistas mediante un cuestionario online/Computer Assisted Web Interview (CAWI) a una muestra representativa a nivel nacional >50 años. La encuesta constaba de 34 ítems divididos en 2 bloques. Se consideró presencia de QSM cuando en la pregunta 1 el sujeto contestaba que ‘Sí’ tenía algún problema de memoria. Resultados Se entrevistó a 2.300 personas (53,7% mujeres; 23,9% ≥75 años). El 31% contestaron que consideraban que tenían un problema de memoria (sin diferencias entre sexos, media de tiempo con problemas de memoria de 3,0 años). Se observó mayor prevalencia de QSM en ≥75 años (44%). El 90% no incluían ningún alimento específico en su dieta para sus problemas de memoria, y tampoco estaban tomando productos farmacéuticos, complementos de la dieta o suplementos nutricionales (92%). El 78% de los entrevistados con QSM no han consultado a profesionales sanitarios por sus problemas de memoria. Conclusiones Las QSM tienen una prevalencia considerable en nuestro medio, afectando a casi un tercio de los individuos >50 años. La mayoría de los entrevistados con quejas de memoria no buscó el consejo/recomendación de profesionales sanitarios con respecto a las mismas. (AU)

Introduction Subjective memory complaints (SMC) might be an early sign of further deterioration in cognitive functions. However, no population studies have been published covering all Spain to determine the SMC prevalence. The objective of the present study was to determine the SMC prevalence in the general population residing in Spain >50 years of age and also which related actions were done. Materials and methods Interviews were conducted with a nationally representative sample >50 years of age using an online/computer assisted web interview (CAWI) questionnaire. The survey consisted of 34 items divided into two blocks. Presence of SMC was considered when in question 1 the subject answered that “Yes” he had some memory problem. Results Two thousand three hundred people (53.7% women; 23.9% ≥75 years old) were interviewed. 31% answered that they considered they had a memory problem (no differences between sexes, mean time with memory problems of 3.0 years). A higher prevalence of SMC was observed in ≥75 years old (44%). 90% did not include any specific foods in their diet for their memory problems, neither were taking any pharmaceuticals, diet supplements or nutritional supplements (92%). 78% of those interviewed with SMC have not consulted health professionals for their memory problems. Conclusions SMC are considerably prevalent in our environment affecting almost a third of people ≥50 years of age. Most of the interviewees with SMC did not go to health professionals to manage their SMC. (AU)

[Prevalence of subjective memory complaints: Population study in Spain]. / Prevalencia de quejas subjetivas de memoria: estudio poblacional en España.

INTRODUCTION: Subjective memory complaints (SMC) might be an early sign of further deterioration in cognitive functions. However, no population studies have been published covering all Spain to determine the SMC prevalence. The objective of the present study was to determine the SMC prevalence in the general population residing in Spain >50 years of age and also which related actions were done. MATERIALS AND METHODS: Interviews were conducted with a nationally representative sample >50 years of age using an online/computer assisted web interview (CAWI) questionnaire. The survey consisted of 34 items divided into two blocks. Presence of SMC was considered when in question 1 the subject answered that "Yes" he had some memory problem. RESULTS: Two thousand three hundred people (53.7% women; 23.9% ≥75 years old) were interviewed. 31% answered that they considered they had a memory problem (no differences between sexes, mean time with memory problems of 3.0 years). A higher prevalence of SMC was observed in ≥75 years old (44%). 90% did not include any specific foods in their diet for their memory problems, neither were taking any pharmaceuticals, diet supplements or nutritional supplements (92%). 78% of those interviewed with SMC have not consulted health professionals for their memory problems. CONCLUSIONS: SMC are considerably prevalent in our environment affecting almost a third of people ≥50 years of age. Most of the interviewees with SMC did not go to health professionals to manage their SMC.

The impact of docosahexaenoic acid on maternal mental health: scoping review / El impacto del ácido docosahexaenoico en la salud mental materna: revisión sistematizada de la literatura

Docosahexaenoic acid (DHA) is a polyunsaturated essential fatty acid from the omega-3 series that appears to be key to perinatal mental health. For this, the aim of this review is to evaluate the effect of DHA on maternal mental health during pregnancy and lactation with respect to depression and anxiety. The present scoping review was carried out following the methodology of Arksey and O’Malley (2005). The selection of studies was carried out in accordance with PRISMA by means of systematic searches in the PubMed, Scopus, PsycINFO and Medline databases. The results classified according to the effectiveness of DHA. In most (n = 9) of the 14 studies finally included, DHA plasma levels with or without other polyunsaturated omega-3 fatty acids were significantly lower in pregnant women with depressive and anxiety symptoms. However, no study reported a beneficial effect of DHA on mental health during the postpartum period. The majority used detection method was the Edinburgh Postpartum Depression Scale (n = 11). The prevalence of depressive symptoms ranged between 5.9 % and 50 %. As a conclusion, although more research is needed in this area, these exploratory results suggest that DHA could play an important role in preventing the pathogenesis of depression and anxiety during gestation.(AU)

El ácido docosahexaenoico (DHA) es un ácido graso esencial poliinsaturado de la serie omega-3 que parece ser clave para la salud mental perinatal. Por ello, el objetivo de esta revisión es evaluar el efecto del DHA sobre la salud mental materna durante el embarazo y la lactancia con respecto a la depresión y la ansiedad. La presente revisión se llevó a cabo siguiendo la metodología de Arksey y O’Malley (2005). La selección de estudios se realizó de acuerdo con PRISMA mediante búsquedas sistemáticas en las bases de datos PubMed, Scopus, PsycINFO y Medline. Los resultados se catalogaron según la eficacia del DHA. En la mayoría (n = 9) de los 14 estudios finalmente incluidos, los niveles plasmáticos de DHA con o sin otros ácidos grasos omega-3 poliinsaturados fueron significativamente más bajos en mujeres embarazadas con síntomas de depresión y ansiedad. Sin embargo, ningún estudio informó un efecto beneficioso del DHA sobre la salud mental durante el periodo posparto. El método de detección más utilizado fue la Escala de Depresión Posparto de Edimburgo (n = 11). La prevalencia de síntomas depresivos osciló entre el 5,9 % y el 50 %. Como conclusión, aunque se necesita más investigación en este ámbito, los resultados exploratorios parecen indicar que el DHA juega un papel importante en la prevención de la patogenia de la depresión y la ansiedad durante el periodo de gestación.(AU)

The impact of docosahexaenoic acid on maternal mental health: scoping review.

Introduction: Docosahexaenoic acid (DHA) is a polyunsaturated essential fatty acid from the omega-3 series that appears to be key to perinatal mental health. For this, the aim of this review is to evaluate the effect of DHA on maternal mental health during pregnancy and lactation with respect to depression and anxiety. The present scoping review was carried out following the methodology of Arksey and O'Malley (2005). The selection of studies was carried out in accordance with PRISMA by means of systematic searches in the PubMed, Scopus, PsycINFO and Medline databases. The results classified according to the effectiveness of DHA. In most (n = 9) of the 14 studies finally included, DHA plasma levels with or without other polyunsaturated omega-3 fatty acids were significantly lower in pregnant women with depressive and anxiety symptoms. However, no study reported a beneficial effect of DHA on mental health during the postpartum period. The majority used detection method was the Edinburgh Postpartum Depression Scale (n = 11). The prevalence of depressive symptoms ranged between 5.9 % and 50 %. As a conclusion, although more research is needed in this area, these exploratory results suggest that DHA could play an important role in preventing the pathogenesis of depression and anxiety during gestation.

Introducción: El ácido docosahexaenoico (DHA) es un ácido graso esencial poliinsaturado de la serie omega-3 que parece ser clave para la salud mental perinatal. Por ello, el objetivo de esta revisión es evaluar el efecto del DHA sobre la salud mental materna durante el embarazo y la lactancia con respecto a la depresión y la ansiedad. La presente revisión se llevó a cabo siguiendo la metodología de Arksey y O'Malley (2005). La selección de estudios se realizó de acuerdo con PRISMA mediante búsquedas sistemáticas en las bases de datos PubMed, Scopus, PsycINFO y Medline. Los resultados se catalogaron según la eficacia del DHA. En la mayoría (n = 9) de los 14 estudios finalmente incluidos, los niveles plasmáticos de DHA con o sin otros ácidos grasos omega-3 poliinsaturados fueron significativamente más bajos en mujeres embarazadas con síntomas de depresión y ansiedad. Sin embargo, ningún estudio informó un efecto beneficioso del DHA sobre la salud mental durante el periodo posparto. El método de detección más utilizado fue la Escala de Depresión Posparto de Edimburgo (n = 11). La prevalencia de síntomas depresivos osciló entre el 5,9 % y el 50 %. Como conclusión, aunque se necesita más investigación en este ámbito, los resultados exploratorios parecen indicar que el DHA juega un papel importante en la prevención de la patogenia de la depresión y la ansiedad durante el periodo de gestación.

Dietary omega-3 LCPUFA intake in the prevention of neovascular age-related macular degeneration: a systematic review and meta-analysis / La ingesta de AGPICL omega-3 en la prevención de la degeneración macular neovascular relacionada con la edad: revisión sistemática y metaanálisis

Purpose: to evaluate the protective effect of omega-3 long-chain unsaturated fatty acids on the progression of wet age-related macular degeneration (wAMD). Methods: this meta-analysis was designed, implemented, and analyzed in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocol and is reported following PRISMA guidelines. Results: in this study we included 5 observational trials, including 2 cross-sectional studies, 2 case-control studies, and 1 confrontation study. These tests are conducted in the U.S., Europe and Japan, and are of high quality. In general, people with high dietary long-chain omega-3 polyunsaturated fatty acids (omega-3 LCPUFAs) have a lower risk of progression to advanced age-related macular degeneration (AMD) (effect size, ES: 0.51, 95 % CI [0.34, 0.75], I2 = 70 %, p = 0.01). When assessing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) intake and wAMD risk a total of the three above studies were included, which also produced similar results. Conclusions: the highest DHA consumption reduced the risk of disease by 39 % (effect size: 0.61, 95 % CI [0.50, 0.74], I2 = 14 %, p = 0.31); compared with the lowest EPA consumption, the highest EPA consumption reduced the risk of wAMD by 32 % (ES: 0.68, 95 % CI [0.57, 0.82], I2 = 39 %, p = 0.20) (AU)

Propósito: evaluar el efecto protector de los AGPICL omega-3 sobre la degeneración macular húmeda asociada a la edad (DMAE). Métodos: este metaanálisis fue diseñado, implementado y analizado de acuerdo con el protocolo de Metaanálisis de Estudios Observacionales en Epidemiología (MOOSE) y se informa siguiendo las directrices de PRISMA. Resultados: en este estudio se incluyeron 5 ensayos observacionales, entre ellos 2 estudios transversales, 2 estudios de casos y controles y 1 estudio de confrontación. Estos ensayos se realizan en Estados Unidos, Europa y Japón y son de alta calidad. En general, las personas con una dieta alta en ácidos grasos poliinsaturados de cadena larga (AGPICL omega-3) tienen un menor riesgo de progresión hacia la degeneración macular avanzada relacionada con la edad (DMAE) (tamaño del efecto, ES: 0,51, IC 95 % [0,34, 0,75], I2 = 70 %, p = 0,01). Al evaluar la ingesta de ácido docosahexaenoico (DHA) y ácido eicosapentaenoico (EPA) y el riesgo de DMAE se incluyeron en total tres de los estudios anteriores, que también arrojaron resultados similares. Conclusiones: el mayor consumo de DHA redujo el riesgo de enfermedad en un 39 % (tamaño del efecto: 0,61, IC del 95 % [0,50, 0,74], I2 = 14 %, p = 0,31); en comparación con el menor consumo de EPA, el mayor consumo de EPA redujo el riesgo de wAMD en un 32 % (ES: 0,68, IC del 95 % [0,57, 0,82], I2 = 39 %, p = 0,20) (AU)

Dietary omega-3 LCPUFA intake in the prevention of neovascular age-related macular degeneration: a systematic review and meta-analysis.

Introduction: Purpose: to evaluate the protective effect of omega-3 long-chain unsaturated fatty acids on the progression of wet age-related macular degeneration (wAMD). Methods: this meta-analysis was designed, implemented, and analyzed in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocol and is reported following PRISMA guidelines. Results: in this study we included 5 observational trials, including 2 cross-sectional studies, 2 case-control studies, and 1 confrontation study. These tests are conducted in the U.S., Europe and Japan, and are of high quality. In general, people with high dietary long-chain omega-3 polyunsaturated fatty acids (omega-3 LCPUFAs) have a lower risk of progression to advanced age-related macular degeneration (AMD) (effect size, ES: 0.51, 95 % CI [0.34, 0.75], I2 = 70 %, p = 0.01). When assessing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) intake and wAMD risk a total of the three above studies were included, which also produced similar results. Conclusions: the highest DHA consumption reduced the risk of disease by 39 % (effect size: 0.61, 95 % CI [0.50, 0.74], I2 = 14 %, p = 0.31); compared with the lowest EPA consumption, the highest EPA consumption reduced the risk of wAMD by 32 % (ES: 0.68, 95 % CI [0.57, 0.82], I2 = 39 %, p = 0.20).

Introducción: Propósito: evaluar el efecto protector de los AGPICL omega-3 sobre la degeneración macular húmeda asociada a la edad (DMAE). Métodos: este metaanálisis fue diseñado, implementado y analizado de acuerdo con el protocolo de Metaanálisis de Estudios Observacionales en Epidemiología (MOOSE) y se informa siguiendo las directrices de PRISMA. Resultados: en este estudio se incluyeron 5 ensayos observacionales, entre ellos 2 estudios transversales, 2 estudios de casos y controles y 1 estudio de confrontación. Estos ensayos se realizan en Estados Unidos, Europa y Japón y son de alta calidad. En general, las personas con una dieta alta en ácidos grasos poliinsaturados de cadena larga (AGPICL omega-3) tienen un menor riesgo de progresión hacia la degeneración macular avanzada relacionada con la edad (DMAE) (tamaño del efecto, ES: 0,51, IC 95 % [0,34, 0,75], I2 = 70 %, p = 0,01). Al evaluar la ingesta de ácido docosahexaenoico (DHA) y ácido eicosapentaenoico (EPA) y el riesgo de DMAE se incluyeron en total tres de los estudios anteriores, que también arrojaron resultados similares. Conclusiones: el mayor consumo de DHA redujo el riesgo de enfermedad en un 39 % (tamaño del efecto: 0,61, IC del 95 % [0,50, 0,74], I2 = 14 %, p = 0,31); en comparación con el menor consumo de EPA, el mayor consumo de EPA redujo el riesgo de wAMD en un 32 % (ES: 0,68, IC del 95 % [0,57, 0,82], I2 = 39 %, p = 0,20).

Efeitos da ingestão dos ácido docosa-hexaenoico e ácido eicosapentaenoico sobre o sistema nervoso central de indivíduos saudáveis ou com patologias neuropsiquiátricas em diferentes faixas etárias: revisão sistemática / Effects of ingestion of docosahexaenoic acid and eicosapentaenoic acid on the central nervous system of healthy individuals or those with neuropsychiatric pathologies in different age groups: a systematic review

Objetivo: Os ácidos graxos essenciais (AGE) ômega-3 dos tipos ácido eicosapentaenoico (EPA) e ácido docosa-hexaenoico (DHA), são benéficos para o sistema nervoso central (SNC) - com estudos demonstrando seu papel na mielinização, formação de sinapses, além da relação de sua deficiência com o desenvolvimento de patologias neurológicas e psiquiátricas. Portanto, o presente trabalho objetiva avaliar sistematicamente os efeitos da ingestão de EPA/DHA no SNC de humanos em diferentes faixas etárias e estados de saúde neurológica e psiquiátrica. Metodologia: Foi adotado o método PRISMA, a busca por estudos foi realizada na base de dados científicos Medline, sendo incluídos artigos publicados entre 2010-2021, publicados em língua inglesa, ensaios clínicos aleatórios (randomizados), e estudos observacionais. Resultados:11 artigos foram selecionados e, em seguida, categorizados por temas. No desenvolvimento neuropsicomotor infantil, observou-se, com a suplementação, benefícios na aquisição da linguagem e obtenção de escores levemente melhores em testes neurológicos. Em adultos saudáveis, houve indícios de aumento na eficácia do processamento neural. No TDAH em crianças, melhores resultados em testes de atenção. Em indivíduos com esquizofrenia, houve menor perda da espessura cortical. Em idosos com déficit de memória ou doença de Alzheimer, maior oxigenação cerebral, menos inflamação e desaceleração da perda de massa cerebral. Conclusão: Constata-se, pela análise dos estudos, que os AGs EPA/DHA beneficiam o SNC por meio de efeitos no neurodesenvolvimento, função cognitiva, prevenção de doenças e como estratégia terapêutica adjuvante. (AU)

Objective: The omega-3 essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial to the central nervous system (CNS), with studies demonstrating their role in myelination and synaptogenesis. Furthermore, its deficiency was correlated with the development of neurological and psychiatric pathologies. Therefore, the present work aims to systematically evaluate the effects of EPA/DHA ingestion on the CNS of humans in different age groups and neurological and psychiatric health status. Methodology: This study was conducted observing the PRISMA method; the search for studies was performed in the scientific database Medline. The inclusion criteria were articles published between 2010-2021, published in English, randomized clinical trials with humans, and observational studies. Results: 1 1 articles were selected and then categorized by topic. It was observed that in children's neuropsychomotor development the EPA/DHA supplementation benefited language acquisition and provided slightly better scores in neurological tests. In healthy adults, there was found evidence of an increase in the effectiveness of neural processing. In children with ADHD, the consumption of EPA/DHA was linked with better scores on tests of attention. In individuals with schizophrenia, there was less loss of cortical thickness. In older adults with memory deficits or Alzheimer's disease, results such as an increase in brain oxygenation, less inflammation, and slower brain mass loss were found. Conclusion: From the analysis of the studies, it appears that the ingestion of EPA/DHA benefits the CNS through effects on neurodevelopment, cognitive function, disease prevention, and as an adjuvant therapeutic strategy. (AU)

Docosahexaenoic fatty acid nanoencapsulated with Anti-PECAM-1 as strategy to increase atherosclerotic plaque stability / Ácido graxo docosahexaenoico nanoencapsulado com anti-PECAM-1 como uma estratégia para aumentar a estabilidade de placas ateroscleróticas

Cardiovascular diseases (CVDs) are the main cause of mortality worldwide, being the ischemic heart disease responsible for 85% of deaths. Atherosclerosis is a chronic inflammation of the arteries that underlies ischemic forms of CVD and involves the innate and adaptive immune systems, from initial fatty streak formation to atherosclerotic plaque ruptures, which defines the beginning and end stages of disease, respectively. Recent research on the reduction of systemic inflammation in order to treat CVD is controversial, since results show that this reduced inflammation can also increase patient susceptibility to general infection. Therefore, new tissue-targeting strategies are necessary. Docosahexaenoic fatty acid (DHA) is a natural bioactive precursor of pro-resolving oxylipins that can reduce inflammation. Based on these factors, the objective of this study was to develop a nanocapsule containing algae oil as a DHA source and apply anti-PECAM-1 on its surface to drive it to the inflamed endothelium. Initially, a surface-functionalized metal-complex multi-wall nanocapsule containing algae oil in its nucleus (MLNC-DHA-a1) was developed. This nanocapsules presented a mean diameter of 163 ± 5 nm, was spherical in shape, showed 94.80% conjugation efficiency using 200 µg/mL of anti-PECAM-1 on the surface, and did not show significant toxicity toward HUVECs at concentrations from 0.14 to 2.90x1011 nanocapsules/mL. The nanocapsules were also stable for 2 h, sufficient time to allow for clinical applications. In cell viability assays, concentrations of 0.14 to 1.40x1011 nanocapsules/mL did not significantly affect the viability of immortalized murine macrophages (RAW 264.7) and U-937 cells after 24, 48, and 72 h of treatment. Finally, macrophages were incubated with 0.75x1011 MLNC-DHA-a1 nanocapsules/mL for 4 h and showed a significant uptake, observed using dark-field hyperspectral microscopy (CytoViva®). Once inside murine macrophages (RAW 264.7), MLNC-DHA-a1 nanocapsules promoted a strong increase in M2 phenotype polarization compared to non-treated control cells. Our results suggest that DHA-enriched algae oil, as part of a lipid core nanocapsules, does not reduce cell viability and improves macrophage phenotype, making it a promising potential therapy for controlling chronic inflammation and healing or stabilizing atherosclerotic plaques

As doenças cardiovasculares (DCVs) são a principal causa de mortalidade no mundo, sendo os eventos isquêmicos responsáveis por 85% das mortes. A aterosclerose é uma inflamação crônica das artérias associada aos eventos isquêmicos das DCVs, na qual o sistema imunológico inato e adaptativo estão envolvidos desde a formação inicial das estrias gordurosas até a ruptura das placas ateroscleróticas. Pesquisas recentes direcionadas à redução da inflamação sistêmica têm mostrado resultados controversos, pois essa abordagem pode aumentar a susceptibilidade do paciente a infecções. Nesse sentido, novas estratégias direcionadas ao tecido lesionado são necessárias. No que se refere a medicamentos anti-inflamatórios ou suplementos alimentares, o ácido docosaexaenóico (DHA) tem sido relatado como um precursor natural de oxilipinas pró- resolutivas. Baseado nesse contexto, o objetivo deste estudo foi desenvolver nanocápsulas contendo óleo de alga como fonte de DHA e vetorizar essas nanopartículas com o anticorpo antiPECAM-1 em sua superfície, visando direcioná-las ao endotélio inflamado. Inicialmente, a nanocápsula multiparede metal-complexa funcionalizada contendo óleo de alga em seu núcleo (MLNC-DHA-a1) foi desenvolvida, apresentando um diâmetro médio de 163 ± 5 nm, formato esférico, onde a eficiência de conjugação do anti-PECAM-1 (200 µg/mL) foi de 94,80% sem toxicidade significativa em HUVECs nas concentrações de 1.14 a 2.9 x 1011 nanocápsulas/mL. As nanocápsulas apresentaram uma estabilidade de 2h, o que representa tempo suficiente para a sua aplicação clínica. A seguir, ensaios de viabilidade celular foram realizados em outras linhagens de células para avaliar a toxicidade das nanocápsulas. As concentrações de 0.14 a 1.40 x 1011 de nanocápsulas/mL não afetaram significativamente a viabilidade celular de macrófagos murinos imortalizados (RAW 264.7) e U-937 após 24, 48 e 72 h de tratamento. Por fim, os macrófagos (RAW 264.7) foram incubados com 0.75 x 1011 MLNC-DHA-a1/mL durante 4 h e apresentam uma captação significativa das nanocápsulas, observada por microscopia hiperespectral de campo escuro (CytoViva®). Uma vez captadas pelos macrófagos murinos imortalizados (RAW 264.7), as nanoformulações MLNC-DHA-a1 promoveram um forte aumento da polarização do fenótipo M2 em comparação com as células controle não tratadas. Nossos resultados sugerem que o óleo de alga rico em DHA presente no núcleo lipídico das nanocápsulas, não reduziu a viabilidade celular e estimulou uma maior polarização de macrófagos para o tipo M2, sendo assim uma terapia potencial para controlar a inflamação crônica e cicatrizar ou estabilizar placas ateroscleróticas

Efecto de la suplementación con omega-3 durante la gestación y la lactancia sobre la composición de ácidos grasos de la leche materna en los primeros meses de vida: una revisión narrativa / Effect of omega-3 supplementation during pregnancy and lactation on the fatty acid composition of breast milk in the first months of life: a narrative review

Los ácidos grasos poliinsaturados de cadena larga omega-3 son esenciales, por lo que deben aportarse a través de la dieta al ser su síntesis biológica limitada; por ello es imprescindible administrarlos para lograr cubrir los requerimientos durante los estadios fisiológicos como el embarazo y la lactancia. Se realizó una revisión narrativa de los efectos de la suplementación de omega-3 durante los periodos de embarazo y lactancia en la composición de ácidos grasos de la leche materna en los primeros meses de vida. En ella se analizaron siete estudios clínicos aleatorizados, de los que se obtuvo un aumento significativo de las concentraciones de ácido docosahexaenoico (DHA) en la leche materna (LM) después de la suplementación, en comparación con los grupos de control. Un estudio evaluó la dosis necesaria para alcanzar un 8 % de DHA en los eritrocitos y un 1 % de DHA en la LM, alcanzándose estos niveles con una suplementación cercana a 1 g de ácido docosahexaenoico + ácido eicosapentaenoico (EPA). Finalmente, se encontró un ensayo que utilizó la suplementación con pequeños aportes de lípidos (0,59 g de ácido α-linolénico (ALA)), sin generar cambios significativos en la composición de DHA de la LM pero sí en el contenido de ALA. Por lo tanto, se infiere que la suplementación con omega-3 modifica de forma beneficiosa los niveles de DHA y EPA en la composición de la LM en las mujeres embarazadas y durante la etapa de lactancia, aunque son necesarios más estudios para identificar las dosis, los tiempos, los efectos beneficiosos sobre el desarrollo y las formas de entrega más eficientes de la suplementación con omega-3. (AU)

Omega-3 long-chain, polyunsaturated fatty acids are essential, so they must be provided through the diet, as their biological synthesis is limited, making it essential to meet their requirements during physiological stages such as pregnancy and lactation. A narrative review was conducted on the effects of omega-3 supplementation during pregnancy and lactation on the fatty acid composition of breast milk in the first months of life. Seven randomized clinical studies were analyzed, showing a significant increase in docosahexaenoic acid (DHA) concentration in breast milk (BM) post-supplementation, compared to control groups. One study evaluated the dose needed to achieve 8 % DHA in erythrocytes and 1 % DHA in BM, reaching these levels with a supplementation close to 1 g of docosahexaenoic acid + eicosapentaenoic acid (EPA). Finally, a trial was found that used supplementation with small lipid contributions (0,59 g α-linolenic acid (ALA)), without generating significant changes in the DHA composition of LM, but in the ALA content. Therefore, it is inferred that omega-3 supplementation beneficially modifies DHA and EPA levels in the composition of BM in pregnant women and during the lactation stage, although further studies are needed to identify doses, times, beneficial effects on development, and more efficient forms of delivery of omega-3 supplementation. (AU)

[Effect of omega-3 supplementation during pregnancy and lactation on the fatty acid composition of breast milk in the first months of life: a narrative review]. / Efecto de la suplementación con omega-3 durante la gestación y la lactancia sobre la composición de ácidos grasos de la leche materna en los primeros meses de vida: una revisión narrativa.

INTRODUCTION: Omega-3 long-chain, polyunsaturated fatty acids are essential, so they must be provided through the diet, as their biological synthesis is limited, making it essential to meet their requirements during physiological stages such as pregnancy and lactation. A narrative review was conducted on the effects of omega-3 supplementation during pregnancy and lactation on the fatty acid composition of breast milk in the first months of life. Eight randomized clinical studies were analyzed, showing a significant increase in docosahexaenoic acid (DHA) concentration in breast milk (BM) post-supplementation, compared to control groups. One study evaluated the dose needed to achieve 8 % DHA in erythrocytes and 1 % DHA in BM, reaching these levels with a supplementation close to 1 g of docosahexaenoic acid + eicosapentaenoic acid (EPA). Finally, a trial was found that used supplementation with small lipid contributions (0,59 g α-linolenic acid (ALA)), without generating significant changes in the DHA composition of LM, but in the ALA content. Therefore, it is inferred that omega-3 supplementation beneficially modifies DHA and EPA levels in the composition of BM in pregnant women and during the lactation stage, although further studies are needed to identify doses, times, beneficial effects on development, and more efficient forms of delivery of omega-3 supplementation.

INTRODUCCIÓN: Los ácidos grasos poliinsaturados de cadena larga omega-3 son esenciales, por lo que deben aportarse a través de la dieta al ser su síntesis biológica limitada; por ello es imprescindible administrarlos para lograr cubrir los requerimientos durante los estadios fisiológicos como el embarazo y la lactancia. Se realizó una revisión narrativa de los efectos de la suplementación de omega-3 durante los periodos de embarazo y lactancia en la composición de ácidos grasos de la leche materna en los primeros meses de vida. En ella se analizaron ocho estudios clínicos aleatorizados, de los que se obtuvo un aumento significativo de las concentraciones de ácido docosahexaenoico (DHA) en la leche materna (LM) después de la suplementación, en comparación con los grupos de control. Un estudio evaluó la dosis necesaria para alcanzar un 8 % de DHA en los eritrocitos y un 1 % de DHA en la LM, alcanzándose estos niveles con una suplementación cercana a 1 g de ácido docosahexaenoico + ácido eicosapentaenoico (EPA). Finalmente, se encontró un ensayo que utilizó la suplementación con pequeños aportes de lípidos (0,59 g de ácido α-linolénico (ALA)), sin generar cambios significativos en la composición de DHA de la LM pero sí en el contenido de ALA. Por lo tanto, se infiere que la suplementación con omega-3 modifica de forma beneficiosa los niveles de DHA y EPA en la composición de la LM en las mujeres embarazadas y durante la etapa de lactancia, aunque son necesarios más estudios para identificar las dosis, los tiempos, los efectos beneficiosos sobre el desarrollo y las formas de entrega más eficientes de la suplementación con omega-3.

Evaluación oxidativa, microbiológica, sensorial y perfil de ácidos grasos de un yogur con ácido docosahexaenoico (DHA) extraído de aceite de microalgas / Oxidative, sensory and fatty acid profile evaluation of a yogurt with docosahexaenoic acid (DHA) extracted from microalgae oil

RESUMEN Las necesidades de ácido docosahexaenoico (DHA), se incrementan en la mujer gestante para el desarrollo visual y neurológico del feto y el lactante. En este trabajo, se desarrolló y se evaluó un yogur adicionado con aceite de microalgas, que contribuyera a la recomendación dietaria de DHA en mujeres gestantes y lactantes. Se diseñaron tres formulaciones de yogur con 0,075; 0,125 y 0,175% de aceite de microalga y se compararon con una muestra control. Se evaluaron propiedades fisicoquímicas, sensoriales, microbiológicas, perfil de ácidos grasos, potencial antioxidante (ABTS, fenoles totales) y peroxidación lipídica (sustancias reactivas al ácido tiobarbitúrico [TBARS]). Los yogures adicionados con el aceite de microalga cubrieron en 30, 45 y 63% las recomendaciones de DHA para mujeres gestantes y lactantes por porción (200 mL). Se observó estabilidad del ácido graso, excepto en la muestra de mayor adición del aceite. La muestra con adición de 0,125% de aceite de microalga fue la de mejor calificación por el panel sensorial. Todas las muestras cumplieron con el estándar microbiológico y fisicoquímico para un yogur entero adicionado con dulce. Se observó potencial antioxidante promisorio en el yogur, capaz de proteger el DHA. Se concluye que las bebidas lácteas como el yogur son matrices adecuadas para la adición de aceite de microalga con la finalidad de aumentar el DHA en la dieta, especialmente en etapas en que las necesidades de este componente son más altas, como en periodo de gestación y lactancia.

ABSTRACT The needs for docosahexaenoic acid (DHA) are increased during pregnancy for the visual and neurological development of the fetus and the breastfed infant. In this study, a yogurt with microalgae oil added to contribute to the dietary recommendation of DHA in pregnant and breastfeeding women was developed and evaluated. Three yogurt formulations were designed with 0.075; 0.125 and 0.175 microalgae oil percentage and compared with a control sample. Fatty acid profile, antioxidant potential (ABTS, total phenols), lipid peroxidation (thiobarbitrical acid reactive substances [TBARS]), physicochemical, sensory, and microbiological properties were evaluated. Yogurts with microalgae oil added covered 30, 45 and 63% of DHA recommendations for pregnant and breastfeeding women per portion (200 mL). Fat acid stability was observed, except in the one with the greatest oil addition. The sample with 0.125% of microalgae oil added was rated the highest by the sensory panel. All samples met the microbiological and physicochemical standard for a whole yogurt added with sugar. Promising antioxidant potential capable of protecting DHA was observed in the yogurt. We conclude that dairy drinks such as yogurt are suitable matrices for adding microalgae oil in order to increase DHA in the diet, especially in stages where the needs of this component are higher as is the case during pregnancy and lactation periods.

Ácidos grasos en cepas de microalgas del Banco de Germoplasma de Organismos Acuáticos del Instituto del Mar del Perú (IMARPE)

Se determinó la composición de ácidos grasos de 54 cepas microalgales colectadas del Perú y mantenidas en el Banco de Germoplasma de Organismos Acuáticos (IMARPE) con la finalidad de determinar su uso nutricional en la acuicultura. Para ello se realizaron cultivos en un volumen de 50 mL y se determinaron los porcentajes relativos de ácidos grasos mediante transesterificación directa y cromatografía de gases. En el grupo Chlorophyta las microalgas que presentaron los mayores valores de porcentaje relativo de ácidos grasos fueron Chlamydomonas reinhardtii (16:0; 41.2%), Scenedesmus obtusus (18:1n-7; 33.6%), Acutodesmus dimorphus (18:1n-9; 37.1%), Desmodesmus armatus (18:3n-3; 32.2%) y Tetraselmis contracta (16:4n-3; 16.5%). En cambio en el grupo Bacillariophyta, los ácidos grasos más abundantes fueron 16:1n-7 en Chaetoceros didymus (20.2%), 18:4n-3 en Navicula sp. (28.3%) y EPA en Asterionellopsis sp. (31.5%). Por otro lado, en el grupo Dinophyta, todas las cepas superaron el 20% de DHA, en particular, la cepa de Akashiwo sanguinea presentó el mayor porcentaje relativo de este ácido graso (29.9%) y de los ácidos grasos 16:0 (24.8%) y EPA (16%). Se discute el uso de estas cepas según su contenido de ácidos grasos.

In This work, we determinate the fatty acids composition and their nutritional value in 54 microalgal strains, collected from Peru and stored in Banco de Germoplasma de Organismos Acuáticos (IMARPE). The cultures were grown to 50 mL and analyzed by direct transesterification and gas chromatography. In the Chlorophyta group, the microalgaes that present the highest relative percentage of fatty acids were Chlamydomonas reinhardtii (16:0; 41.2%), Scenedesmus obtusus (18:1n-7; 33.6%), Acutodesmus dimorphus (18:1n-9; 37.1%), Desmodesmus armatus (18:3n-3; 32.2%) and Tetraselmis contracta (16:4n-3; 16.5%). Moreover in the Bacillariophyta group, the most abundant fatty acids were 16:1n-7 in Chaetoceros didymus (20.2%), 18:4n-3 in Navicula sp. (28.3%) and EPA in Asterionellopsis sp. (31.5%). By the other hand, in the Dinophyta group, all strains exceed the 20% of DHA, in particular Akashiwo sanguinea, it was strain to have the highest percentage of this fatty acid (29.9%) in addition to 16: 0 (24.8%) and EPA (16%). We discussed uses of these strains is according to their fatty acids content.

Nutritional supplements with omega 3 in retinal disease: Relationship between volume and concentration in commercial products. / Suplementación nutricional con omega 3 en retina: relación entre volumen y concentración en productos comerciales.

OBJECTIVE: To analyse the morphometric characteristics and the concentration of (docosahexaenoic acid) DHA and eicosapentaenoic acid (EPA) of the different nutritional supplements with omega 3 available on the market for retinal disease. MATERIAL AND METHODS: A double-blind study was conducted with a single observer, of the different omega 3 supplementation tablets sample marketed in Spain. The length of the tablet, the concentration of omega 3 in total, as well as DHA and EPA were studied separately using the amount provided by the manufacturer and the volume of the capsule calculated from the development of a specific formula for it. RESULTS: A total of 10 different nutritional supplements were included. The mean of total omega 3, DHA and EPA was 383.10±160.90, 210.72±93.3, and 112.34±140.98mg, respectively. The mean size of the capsules was 14.77±0.19×8.13±0.09mm The smallest sized capsule was that of Oftan macula omega® (Esteve, Barcelona, Spain). Brudymacula® (Brudylab, Barcelona, Spain) and Brudyretina 1.5 g® (Brudylab, Barcelona, Spain) tablets contained more DHA, with Nutrof omega® (Thea Laboratories, Barcelona, Spain) having the lowest concentration of omega 3, DHA and EPA, per tablet. CONCLUSION: There are significant differences in size, volume, quantity, and concentration of omega 3 and its derivatives, between different commercial preparations. Only the knowledge of the characteristics of the nutritional supplements will enable us to provide a more personalised indication of their use for our patients.

Ômega 3 na gestação e seus benefícios / Omega 3 during pregnancy and its benefits

O objetivo desta pesquisa é levantar a literatura científica sobre os benefícios do Ômega-3 na gestação, que se deu pelas bases de dados Scientifc Electronic Library Online (Scielo), Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs), Literatura Internacional em Ciências de Saúde (Medline) e National Library of Medicine (Pubmed) e Cochrane em literaturas nacionais e internacionais. Nesta pesquisa pode-se verificar que o ácido docosahexaenoico (DHA) é considerado como o principal tipo de Ômega-3 pelo fato de proporcionar benefícios para a saúde, que vão desde o desenvolvimento do cérebro e da retina do bebê, os quais têm início a partir da suplementação da mãe já na gestação. O acúmulo do Ômega-3 ocorre no último trimestre da gestação e o transporte se dá através da placenta, sendo depositado no cérebro e na retina do concepto. Ocorre também um acúmulo simultâneo nas glândulas mamárias durante esta fase. O recomendado pelo consenso é de 200mg/dia, independentemente da fonte utilizada para suplementação. O adequado aporte de Ômega-3 na gestação e no pós-natal tem influência positiva no desenvolvimento visual e do sistema nervoso do recém-nascido, influenciando também na inteligência e na intelectualidade do indivíduo na vida adulta. O Ômega-3 é importante também na prevenção e tratamento de diversas doenças como obesidade, doenças cardiovasculares, imunológicas, câncer de cólon, entre outras.(AU)

The objective of this research is to raise the scientific literature on the benefits of omega-3 during pregnancy, which occurred in research in databases Scientifc Electronic Library Online (Scielo), Latin American and Caribbean Health Sciences (Lilacs) , International Literature in Health Sciences (MEDLINE) and national Library of Medicine (PubMed) and the Cochrane in national and international literature, which can be seen that docosahexaenoic acid (DHA) is considered as the main type of Omega-3, the fact provide health benefits ranging from brain development and the baby's retina, which begins from the mother during pregnancy supplementation already. The Omega-3 accumulation occurs in the last trimester of pregnancy and the transport is through the placenta being deposited in the brain and retina of the fetus. It is also a simultaneous accumulation in the mammary glands during this phase. The recommended by consensus is 200 mg / day, regardless of the source used for supplementation. Adequate intake of omega-3 during pregnancy and in the postnatal has positive influences on visual development and the nervous system of the newborn, influencing also the intelligence and the individual intellect in adulthood. The Omega-3 is also important in the prevention and treatment of various diseases as obesity, cardiovascular, immune disorders, colon cancer, among others.(AU)

Efectos neuroprotectores del ácido araquidónico y del ácido docosahexaenoico en las etapas extremas de la vida: Una visión integradora / Neuroprotective effects of arachidonic and docosahexaenoic acid in the extreme stages of life: An integrative view

RESUMEN El estudio focalizado en dilucidar el rol neuroprotector del ARA y del DHA a lo largo del ciclo vital ha cobrado cada vez más interés puesto que se continúan descubriendo mecanismos mediante los cuales estos ácidos grasos poliinsaturados de cadena larga (AGPICL) modulan el metabolismo. Tanto el ARA como el DHA se encuentran depositados en los lípidos de las membranas de las células que forman la materia gris y representan aproximadamente el 25% del contenido total de ácidos grasos cerebrales. El ARA y el DHA tienen efectos sobre el crecimiento y la diferenciación neuronal a través de la modulación de las propiedades físicas de la membrana, de la transducción de señales asociada a proteínas G y la modulación de la expresión génica, adquiriendo un rol relevante en la neuro-génesis y el desarrollo cerebral. Además, se les atribuye un rol neuroprotector en patologías neurodegenerativas como la enfermedad de Alzheimer y la enfermedad de Parkinson, pudiendo disminuir la disfunción mitocondrial, la neuro-inflamación y el estrés oxidativo, expresiones características de estas patologías. La presente revisión analiza y discute acerca del rol del ARA y del DHA en la neuro-protección y en la neurodegeneración a través de una visión integradora.

ABSTRACT The study focused on elucidating the neuro-protective effects of ARA and DHA throughout the life cycle has become of increasingly interest since the continue discovering of mechanisms by which these long-chain polyunsaturated fatty acids (LCPUFA) modulate the metabolism. Both ARA and DHA are deposited into the membrane lipids of the cells that form the gray matter of the brain and represent approximately 25% of the total content of cerebral fatty acids. ARA and DHA have effects on the growth and neuronal differentiation through the modulation of the physical properties of the membrane, the signal transduction associated to G proteins and by the modulation of gene expression, acquiring a relevant role in neurogenesis and brain development. In addition, it is attributed to these fatty acids a neuro-protective role in neurodegenerative pathologies such as Alzheimer's disease and Parkinson's disease by decreasing the mitochondrial dysfunction, neuroinflammation and oxidative stress, characteristic of these pathologies. This review analyzes and discusses the role of ARA and DHA in neuro-protection and neuro-degeneration through an integrative vision.

Suplementos nutricionales en el deterioro cognitivo y la enfermedad de Alzheimer: revisión de la literatura / Dietary supplements in cognitive impairment and Alzheimer's disease: a literature review

RESUMEN OBJETIVOS: Evaluar los efectos del consumo de ácidos grasos omega 3 en forma de suplementos, complementos o alimentos sobre la función cognitiva de los adultos. MÉTODOS: Se realizó una revisión de la literatura en las bases de datos Medline y Embase, buscando ensayos clínicos, estudios observacionales, revisiones sistemáticas y estudios experimentales que relacionaran los ácidos grasos omega 3 con función cognitiva y Alzheimer. RESULTADOS: La mayoría de los estudios relacionó la suplementación de cápsulas con omega 3, el consumo de pescado u otros alimentos con contenido de omega 3, con resultados en pruebas de función cognitiva, desenlace de enfermedad o imágenes diagnósticas, encontrando en general efectos benéficos, que parecen ser mayores en personas sanas y con mejor función cognitiva de base. Hubo diferencias en los resultados encontrados en los ensayos clínicos y revisiones sistemáticas, que podrían atribuirse a la variabilidad en las dosis de la suplementación, el tiempo de seguimiento y la manera en que se midió la función y el deterioro cognitivo. CONCLUSIÓN: El consumo de ácidos grasos omega 3 en forma de suplementos, complementos o alimentos ricos en estos como el pescado parece tener efectos benéficos en la función cognitiva de las personas adultas.

SUMMARY OBJECTIVES: To evaluate the effects of omega 3 fatty acids consumption in the form of dietary supplement, complement or food-products presentation on adult cognitive function. METHODS: A literature review in two databases (Medline and Embase) was undertaken, searching for clinical trials, observational studies, systematic reviews and experimental studies concerning omega-3 fatty acids and their relation with cognitive function and Alzheimer's disease. RESULTS: Most studies linked supplementation with omega-3 capsules and consumption of fish and other omega-3 containing foods with results in cognitive function testing, outcomes in diseases or diagnostic imaging and found beneficial effects, which seem to be stronger in healthier persons with better cognitive function at baseline. There were differences in the results found in clinical trials and systematic reviews, which could be attributable to the variability in the supplementation dose, the length of follow-up and the methods used to assess cognitive function and decline. CONCLUSION: The use of omega-3 fatty acids in supplement, complement or food-products presentation seems to have beneficial effects in the cognitive function of healthy adults.

[Polyunsaturated omega-3 fatty acids and systemic lupus erythematosus: what do we know?]. / Ácidos graxos poli-insaturados ômega-3 e lúpus eritematoso sistêmico: o que sabemos?

Various studies have demonstrated the impact of omega-3 fatty acids on the concentration of C reactive protein (CRP), pro-inflammatory eicosanoids, cytokines, chemokines and other inflammatory mediators. Therefore, the supplementation of these types of lipids may represent additional option treatment for chronic systemic diseases, such as Systemic Lupus Erythematous and other rheumatic diseases. The role of these lipids has not been well established, yet. However, it seems there is a direct relationship between its intake and the decrease of the disease clinical manifestations as well as of the inflammatory status of the patients. Thus, the aim of this manuscript is to present a thorough review on the effects of omega-3 fatty acids in patients with SLE. Bibliographic data set as the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) were searched using as key words: systemic lupus erythematous (SLE), polyunsaturated fatty acids omega-3, eicosapentanoic acid (EPA), docosahexanoic acid (DHA), antioxidants and diet. Manuscripts published up to September 2013 were included. There were 43 articles related to the topic, however only 15 pertained human studies, with three review articles and 12 clinical studies.

Ácidos graxos poli-insaturados ômega-3 e lúpus eritematoso sistêmico: o que sabemos? / Polyunsaturated omega-3 fatty acids and systemic lupus erythematosus: what do we know?

Diversos estudos têm demonstrado a habilidade dos ácidos graxos ômega-3 em reduzir asconcentrações de proteína C-reativa (PCR), eicosanoides pró-inflamatórios, citocinas, quimiocinas e de outros biomarcadores da inflamação. Por essas propriedades, a suplementação com essa classe de lipídeos pode representar terapia adicional ao tratamento de doençasinflamatórias crônicas sistêmicas, como o lúpus eritematoso sistêmico (LES) e outrasdoenças reumáticas. O papel dessa classe de lipídeos no LES ainda não está bem estabelecido. No entanto, parece haver relação entre o consumo deste tipo de gordura e a diminuiçãodas manifestações e da atividade inflamatória da doença. Sendo assim, este artigo apresentarevisão da literatura científica sobre os efeitos dos ácidos graxos ômega-3 em pacientescom LES. Realizou-se levantamento bibliográfico junto aos bancos de dados Medical Literature Analysis and Retrieval System Online (MEDLINE) e Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), utizando-se como palavras-chave: lúpus eritematoso sistêmico (LES), ácidos graxos poli-insaturados ômega-3, ácido eicosapentaenoico(EPA), ácido docosahexaenoico (DHA), antioxidantes e dieta. Foram incluídos artigos publicados até setembro de 2013. Quarenta e três artigos relacionados ao tema foram encontrados. Após limitar a busca apenas para estudos realizados em seres humanos foram encontrados 15 artigos, sendo três de revisão e 12 ensaios clínicos.

Various studies have demonstrated the impact of omega-3 fatty acids on the concentration of C reactive protein (CRP), pro-inflammatory eicosanoids, cytokines, chemokines and other inflammatory mediators. Therefore, the supplementation of these types of lipids may represent additional option treatment for chronic systemic diseases, such as Systemic Lupus Erythematous and other rheumatic diseases. The role of these lipids has not been well established, yet. However, it seems there is a direct relationship between its intake and the decrease of the disease clinical manifestations as well as of the inflammatory status of the patients. Thus, the aim of this manuscript is to present a thorough review on the effects of omega-3 fatty acids in patients with SLE. Bibliographic data set as the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) were searched using as key words: systemic lupus erythematous (SLE), polyunsaturated fatty acids omega-3, eicosapentanoic acid (EPA), docosahexanoic acid (DHA), antioxidants and diet. Manuscripts published up to September 2013 were included. There were 43 articles related to the topic, however only 15 pertained human studies, with three review articles and 12 clinical studies.

Ácidos grasos poliinsaturados de cadena larga ω-3 y enfermedad cardiovascular / N-3 long chain polyunsaturated fatty acids and cardiovascular disease

ω-3 Long-chain polyunsaturated fatty acids (ω-3 LCPUFA) of marine origin, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present in fatty fish or blue fish, have different beneficial effects on human health especially at the cardiovascular level. From the late observations in the 1960s, basic, clinic and epidemiological evidence have established significant cardio protective effects for these fatty acids in reducing the morbidity and mortality from the disease. The cardiovascular benefits of ω-3 LCPUFA of marine origin are targeted on various inflammatory and metabolic pathways which are regulated by these fatty acids, particularly in the vascular endothelium, the inflammatory response and cardiac cells activity. EPA and DHA are transformed into a variety of eicosanoids and docosanoids which have strong anti-inflammatory actions antagonizing the proinflammatory actions of ω-6 LCPUFA. The different molecular mechanisms by which these fatty acids exert cardio protective effects and the clinical and epidemiological evidence demonstrating the reduction in the morbidity and mortality from cardiovascular diseases are discussed.

Los ácidos grasos poliinsaturados de cadena larga ω-3 (AGPICL ω-3) de origen marino, principalmente el ácido eicosapentaenoico (EPA) y el ácido docosahexaenoico (DHA), presentes especialmente en pescados grasos o azules, producen diversos efectos saludables en la salud humana, especialmente a nivel cardiovascular. Desde la década de 1960 han surgido múltiples evidencias básico-clínicas y epidemiológicas que establecen que estos ácidos grasos ejercen un significativo efecto cardioprotector, produciendo una disminución de la morbilidad y de la mortalidad por enfermedad cardiovascular. El EPA y el DHA son transformados eicosanoides y docosanoides que tienen poderosos efectos antiinflamatorios y que antagonizan el efecto proinflamatorio de AGPICL ω-6. Los beneficios a nivel cardiovascular atribuidos a los AGPICL ω-3 de origen marino se centran, principalmente, en la regulación de vías metabólicas de la respuesta inflamatoria en el endotelio vascular y en la actividad de las células cardíacas. Esta revisión discute las diferentes evidencias metabólicas, clínicas y epidemiológicas que demuestran como el consumo de AGPICL ω-3 de origen marino puede reducir la morbilidad y mortalidad por enfermedad cardiovascular.